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The third annual RNAi conference, RNAi2008: Functions 
and Applications of Non-coding RNAs, held at St Anne’s 
College,  Oxford,  UK  (13-14  March  2008),  afforded  the 
opportunity  for  participants  from  both  academia  and 
industry  to  convene  and  discuss  recent  work  on  the 
molecular  mechanisms  of  RNA-based  gene  silencing  as 
well as recent advances in harnessing RNAi for research 
and  therapeutics.  The  conference  featured  a  stimulating 
series of talks from experts in the field, and research posters 
were displayed for the full duration of the conference. In 
addition, researchers  had  the  chance to  learn about latest 
commercial products through a trade exhibition, featuring 
companies including Exiqon, Thermo Scientific, Integrated 
DNA  Technologies,  Open  Biosystems,  Polyplus-
transfection,  Eurogentec,  Amaxa,  Panomics  and  Applied 
Biosystems.  
 
THE MECHANISMS OF SILENCING 
 
Active  RISC  (RNA-Induced  Silencing  Complex)  is 
composed  of  single-stranded  siRNA  bound  to  an 
endonucleolytically  active  Argonaute  protein,  which  is 
capable  of  capturing  and  silencing  a  native  mRNA  that 
complements the single-stranded siRNA. In many systems, 
endogenous  siRNA  are  generated  from  a  longer  double-
stranded  RNA  precursor  by  the  ribonuclease  action  of 
Dicer. However, James Parker (University of Oxford, UK) 
highlighted that some PIWI domain proteins may bind small 
RNAs  generated  by  Dicer  independent  mechanisms,  and 
that structural variations in the 5’ phosphate binding motif 
of the PIWI domain might dictate some aspects of small 
RNA  binding  specificity.  This  observation  is  further 
supported by the recent observation of 5’nt specificity of 
Arabidopsis Argonaute proteins (Mi et al, 2008).  
 
Addressing the question of how RISC finds its target, Renée 
Schroeder  (Max  F  Perutz  Laboratories,  Austria)  used  in 
vitro and in vivo assays to show that accessibility  of  the 
target site is directly linked to the efficiency with which it 
cleaves  mRNA,  demonstrating  that  RISC  is  unable  to 
unfold structured RNA. Furthermore, she presented results 
suggesting that RISC interacts with single-stranded RNA in 
a  non-specific  manner  and  promotes  annealing  of  the  5’ 
‘seed’ region of the siRNA (nucleotides 2-7 or 2-8) to the 
target  mRNA.  Ian  Sudbery  (The  Wellcome  Trust Sanger 
Institute)  further  emphasised  the  role  of  the  ‘seed’  in 
understanding siRNA off-target effects. It will be of interest 
to understand the loading and distribution of small RNAs 
between Argonaute proteins in relation to how 5’ and 3’ 
regions  of  siRNA  contribute  to  non-specific  silencing  in 
specific transfection conditions. 
 
GENE SILENCING IN EPIGENETICS 
 
The  importance  of  non-coding  RNAs  (ncRNAs)  in  the 
control of epigenetic regulation has been well characterised 
in the case of Xist-induced X-chromosome inactivation in 
female cells. Denise Barlow (Viennna, Austria) emphasised 
the  increasing  importance  of  macro  ncRNAs  in  the 
regulation  of  imprinted  gene  clusters.  Using  the  Igf2r 
imprinted  cluster,  which  is  silenced  by  a  macro  ncRNA 
known  as  Air,  she  observed  that  repressive  histone 
modifications  (H3-K9m3  and  H4-K20m3)  on  the  silent 
parental Igf2r gene were localised to discrete regions in cis 
to Air transcription. Moreover, using a new embryonic stem 
cell in vitro differentiation model that recapitulates the onset 
of Igf2r silencing, she carried out truncation analysis on Air 
which  indicates  that  transcription  through  the  adjacent 
promoter was necessary for some aspects of silencing, and 
suggested a model of transcriptional interference.  
 
piRNAs IN GERMLINE DEVELOPMENT 
 
Piwi proteins are a subfamily of Argonaute proteins which 
are  specifically  expressed  in  germ  cells  in  vertebrates,  
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where  they  bind  piRNA  and  may  modify  chromatin 
structure.  The  RNAi2008  keynote  speaker,  René  Ketting, 
demonstrated  expression  of  the  zebrafish  PIWI  proteins, 
ZIWI and ZILI, in both the female and male gonads. The 
maternally  transmitted  ZIWI  was  localised  only  in  the 
cytoplasm whereas ZILI could be found in the nucleus as 
well. He created PIWI null mutants and observed that lack 
of ZIWI resulted in loss of germ cells due to apoptosis after 
three weeks, whereas lack of ZILI led to a gradual, non-
apoptotic loss  of germ cells  due to a block  of  germ cell 
differentiation.  Although  most  piRNAs  are  derived  from 
transposable  elements  (TEs),  PIWI  mutants  did  not 
experience increased activation of TEs. Deborah Bourc'his 
(Paris, France) further stressed the importance of silencing 
of TEs in the mammalian germ line by transcriptional and 
post-transcriptional  mechanisms.  She  showed  that 
transcriptional suppression occurs by the regulatory action 
of Dnmt3L, which stimulates DNA methylation by Dnmt3A 
and Dnmt3B. Dnmt3L null mutant mice lost spermatogonia 
and had wide-spread DNA methylation defects as well as 
reactivation  of  hypomethylated  retrotransposons.  Post-
translational  suppression  includes  RNA  editing  by  the 
murine PIWI proteins MILI, MIWI and MIWI2, as well as 
degradation  by  RNAi.  MIWI2  mutants  displayed 
inappropriate activation of TEs, meiotic-progression defects 
in early prophase of meiosis I and progressive loss of germ 
cells with age. These studies suggest that mammalian PIWI 
proteins  and  piRNAs  are  important  in  gene  silencing  by 
regulating TEs through multiple mechanisms. 
 
miRNA EXPRESSION IN DISEASE 
 
Many reports indicate that transcription and/or maturation 
of miRNAs may be significantly altered in the disease state. 
Measuring these changes in activity therefore gives a deeper 
molecular  understanding  and  potential  therapeutic 
applications.  
 
Andrei  Thomas-Tikhonenko  (University  of  Pennsylvania, 
USA) described a molecular model for the repression of the 
miR-15a/16-1 locus by the Pax5 transcription factor, which 
also cooperates with c-Myc to up-regulate key components 
of  the  B-cell  receptor  signalling  pathway  during  B-
lymphomagenesis.  Interestingly,  the  miR-15a/16-1  locus 
seems  to  repress  the  expression  of  the  oncogenic 
transcription factors Myb and Ets1, which in turn are needed 
for Pax5 function. Adam Baker (Exiqon, Denmark) detailed 
Exiquon’s expansion into  the  field  of  cancer  diagnostics, 
indicating  novel  LNA  mercury  microarrays  that  identify 
miRNA transcription profiles of secondary tumours, allow 
identification of the site of the primary tumour, and can give 
insight  into  the  chemotherapy  agents  that  might  be  best 
suited for treatment.  
 
Thomas Thum (Würzburg, Germany) reported the exciting 
observation  that  cardiac  miRNAs  contribute  to  the 
transcriptional  changes  observed  during  heart  failure  by 
reactivation  of  fetal  gene  programs.  Using  an  in  vivo 
delivery  model  for  cholesterol-bound  miRNA  antagonists 
(antagomirs), he was able to silence miR-21, a miRNA that 
is  highly  up-regulated  during  heart  failure,  in  a  mouse 
cardiac hypertrophy heart model, resulting in normalisation 
of  many  genes  and  graphic  prevention  of  myocardial 
hypertrophy. This result generated the pertinent discussion 
as  to  whether  it  might  also  be  possible  to  reverse  tissue 
damage  using  this  technology,  as  tissue  damage  is  often 
significant  before  a  patient  presents  to  a  clinician.  
The  engineering  of  this  technology  into  a  treatment  for 
aspects  of  heart  disease  may  well  illuminate  therapeutic 
avenues for many diseases using anti-miRNA agents.   
 
siRNAs IN THERAPY 
 
Applications  of  RNAi-based  gene  silencing  methods  are 
promising in the treatment of many diseases. Roger Kaspar 
(TransDerm, USA) reported the development of a siRNA 
that specifically targets the keratin 6a (K6a) N171K single 
nucleotide mutation responsible for the dominant negative 
disorder pachyonychia congenita (PC). Using a PC mouse 
model which was obtained by engraftment of bioengineered 
skin equivalents derived from PC patients onto the backs of 
immuno-compromised mice he is currently testing various 
delivery  methods  of  the  siRNA  to  skin.  Additionally  he 
commented  upon  the  progress  of  such  siRNA  towards 
clinical trials in Human subjects, and discussed the potential 
for topical application of siRNA. Matthew Wood (Oxford, 
UK) further described efforts towards an RNAi expression 
system for effective allele-specific silencing of target mutant 
repeat-expanded genes, which he used to selectively silence 
the  mutant  ataxin-7  transcript  responsible  for  SCA7 
(Spinocerebellar ataxia  type  7) in cell culutre.  Using  this 
approach he was able to reduce mutant protein levels and 
restore  the  wild-type  phenotype,  and  hopes  to  further 
validate  this  model  in  vivo  via  direct  application  to  the 
retina.  
 
siRNA DESIGN AND DELIVERY 
 
Even though the use of RNAi is becoming established as a 
powerful  tool  to  identify  gene  function  and  elucidate 
biological  pathways,  there  are  still  some  experimental 
challenges to face, such as the biological efficiency of the 
silencing RNA, its tissue-specific delivery and its specificity 
towards  the  target  with  low  “off-target”  effects.  The 
optimisation of these processes was addressed by many of 
the  RNAi2008  speakers  from  both  academic  and 
commercial backgrounds, and their importance for the use 
of  RNAi  in  research  and  in  the  clinic  was  repeatedly 
emphasised. 
 
Improvements in siRNA action can be obtained by chemical 
modification. By introducing various types of 2’-modified 
locked nucleic acids (LNA) in both strands of the siRNA, 
and 1-2 nicks in the backbone of the sense strand, Jørgen 
Kjems  (Aarhus,  Denmark)  devised  synthetic  sisiRNAs 
(small internally segmented interfering RNAs) that employ 
two 10-12nt sense strand oligos, and demonstrate enhanced 
serum-stability  and  a  potent  long-lasting  gene-silencing 
effect  whilst  reducing  the  number  of  off-target  effects. 
Moreover,  sisiRNAs  permit  heavy  modifications  of  the 
antisense strand which influences the pharmacokinetics of 
the  sisiRNA  significantly.  Dmitry  Samarsky  (RXi 
Pharmaceuticals,  USA)  reported  the  design  of  another 
distinct  class  of  siRNAs  by  RXi  called  rxRNA
TM,  with 
improved  stability  and  silencing  characteristics.  Gwen 
Fewell  (Open  Biosystems,  USA)  presented  the  newly  
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developed  inducible  genome-wide  human  letiviral 
shRNAmir  library,  known  as  TRIPZ,  which  allows 
temporal control  over  the  gene  knockdown. The pTRIPZ 
vector  containing  a  TurboRFP  reporter  for  shRNAmir 
expression showed high levels of induced knockdown with 
low basal expression.  
 
A number of presentations focused on the efficient delivery 
of siRNA into target tissues using non-viral methods. Both 
Jørgen  Kjems  and  Dmitry  Samarsky  demonstrated  the 
successful use of nanoparticles in RNA delivery and their 
potential therapeutic applications in systemic and mucosal 
diseases,  and  Amyotrophic  lateral  sclerosis,  respectively. 
Ludger  Altrogge  (Axama,  Germany)  presented  the 
Nucleofector
®  96-well  Shuttle
®  System  for  effective 
transfection  of  RNA  into  various  “difficult-to-transfect” 
cells  including  primary  cells  in  high  throughput 
applications.  He  reported  successful  siRNA  screening 
experiments on human umbilical vein cells and Jurkat T-
lymphocytes  using  this  technology.  Stephanie  Urschel 
(Thermofisher/Dharmacon,  Germany)  described  the  novel 
Accell
TM  siRNA  delivery  method  which  allows  specific 
target  silencing  in  any  cell  type  including  primary, 
differentiated and “difficult-to-transfect” cells. The passive 
delivery results in higher cell viability due to elimination of 
toxicity,  and  the  lack  of  non-specific  lipid  effects  may 
reduce off-target effects.  
 
Of note was the quite different approach by Justin Teissie 
(Toulouse,  France)  who  made  use  of  the  reversible 
membrane  permeabilisation  resulting  from  electric  field 
pulse application after a local injection of polyelectrolyte to 
deliver siRNA into muscle and tumours. Silencing could be 
achieved  for  two  weeks  in  muscle  and  a  few  days  in 
tumours. However, silencing duration could be prolonged to 
more than two months using plasmids coding for shRNA.  
 
At previous RNAi conferences in Oxford, George Sczakiel 
(Universität zu Lübeck, Germany) reported an alternative 
pathway for RNA uptake by phosphorothioate-stimulated 
internalisation  of  siRNA  into  cells  via  the  caveosomal 
pathway,  and  the  limited  efficacy  resulting  from 
intracellular  trapping  of  a  major  fraction  of  the  siRNA. 
The importance of these observations with respect to both 
therapeutic siRNA delivery and interpretation of biological 
silencing activity  using  different  transfection  reagents  is 
now becoming clear, (e.g. Lytle et al, 2007; Vasudevan et 
al, 2007). This year, Sczakiel demonstrated that ECV-304 
cells,  despite  taking  up  smaller  amounts  of  siRNA 
compared to SKRC-35 cells, showed target suppression; 
whereas  there  was  no  measurable  target  suppression  in 
SKRC-35 cells. He proposed that co-localization of siRNA 
and the human Argonaute protein, Ago2, in the vicinity of 
the rough ER, relates to the extent of target suppression. 
Thus, siRNA is recruited from the site of trapping to the 
site  of  action  in  cells  which  show  biological  efficacy. 
Moreover, he described a cell model with a siRNA-peptide 
conjugate,  allowing  increased  target  inhibition  which 
could provide tools for further mechanical and biological 
studies.  
 
Barbara  Demeneix  (Paris,  France)  described  the 
optimisation of siRNA and shRNA delivery to the neural 
stem cell (NSC) niche in the mouse brain, the organ with 
the  highest  number  of  cell  types  and  with  limited 
accessibility. She was able to deliver siRNA to the NSC 
niche in newborn mouse brain using a combination of a 
cationic  lipid  (Jetsi
TM)  with  a  neutral  lipid  (DOPE),  as 
well  as  shRNA  with  a  hybrid  construct  of  a  cationic 
polymer  (polyethylenimine,  PEI)  with  CMV-H1. 
Moreover,  making  use  of  INTERFERin
®  she  delivered 
siRNA into the neurogenic zone of adult mice. With these 
approaches  she  addressed  the roles  of  thyroid  hormone 
signalling in the control of neural stem cell proliferation 
and  identified  genes  and  receptors  implicated  in  their 
control.  
 
RNAi IN GENE FUNCTION ANALYSIS 
 
RNAi-based gene-specific knockdowns can also provide 
information  on  temporal  and  spatial  control  of  gene 
function during development. Ester Stoeckli (University 
of  Zürich,  Switzerland)  developed  in  ovo  and  ex  ovo 
RNAi  models  to  study  the  molecular  mechanisms 
underlying  the  establishment  of  neural  circuits.  She 
identified Sonic Hedgehog  (Shh) as a guidance  cue  for 
post-commissural  axons  which,  during  early  stages  of 
neural development, is involved in cell differentiation and 
patterning  of  the  dorso-ventral  axis  of  the  spinal  cord. 
Later in development, Shh acts as a chemo-attractant in 
parallel to Netri-1 guiding axons towards the floor plate, 
the  ventral  midline  of  the  spinal  cord.  Interestingly,  as 
soon  as  the  axons  crossed  the  midline  Shh  becomes  a 
chemorepellent due to a receptor switch from Patched to 
Hip (Hedgehog-interacting protein).  
 
Chris Lord (London, UK) proposed the use of genome-
wide RNAi approaches to identify new targets for anti-
cancer  drugs  as  well  as  to  modify  uses  of  existing 
therapeutics.  David  Horn  (London,  UK)  presented  a 
newly  developed  p2T7
TAblue  Tet-on  conditional  RNAi 
vector  which  can  be  used  for  a  systematic  knockdown 
analysis of gene function in the parasite Trypanosomatid. 
 
CONCLUDING REMARKS 
 
The  conference  gave  an  opportunity  to  a  number  of 
speakers, poster presenters and exhibitioners from a wide 
range  of  scientific  and  commercial  backgrounds  to 
present their work and recent advances in RNAi research. 
It  also  created  a  forum  for  discussion  of  new  research 
prospects  and  improvements  in  the  applications  of  the 
technique.  The  fast-paced  field  of  RNAi  appears  to  be 
closer than ever to a successful therapeutic tool, but there 
are still technical hurdles to be overcome, and much to be 
understood about the role of ncRNAs. RNAi2008 inspired 
a  great  deal  of  excitement,  and  has  provided  a  large 
amount of information from which attendees will benefit 
in many respects.   
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